查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067644

神經生物標記免疫檢測市場規模、佔有率和趨勢分析報告：按產品、疾病和細分市場分類（2026-2033 年）

Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Services), By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis), And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

神經系統生物標記免疫檢測測定市場概覽

2025 年全球神經生物標記免疫檢測市場規模估計為 10.8 億美元，預計到 2033 年將達到 21.2 億美元，2026 年至 2033 年的複合年成長率為 8.91%。

這一成長是由神經退化性疾病的日益普遍、對早期診斷的需求不斷成長、微創血液檢測的廣泛普及以及高靈敏度免疫檢測的進步所推動的。

此外，神經生物標記在藥物研發和精準醫療的應用日益廣泛也是推動市場成長的因素之一。對神經系統疾病早期診斷的需求不斷成長，顯著推動了神經生物標記免疫檢測市場的發展。這是因為早期檢測能夠改善治療效果，並實現及時的治療性介入。諸如阿茲海默症神經系統疾病往往難以在早期階段確診，因此迫切需要便捷易用的診斷工具。例如，2025年10月，羅氏公司（F. Hoffmann-La Roche）的Elecsys pTau181獲得了美國食品藥物管理局（FDA）的批准。 Elecsys pTau181是一種用於血液檢測的免疫檢測，旨在支持在臨床和基層醫療機構中早期發現阿茲海默症。這些檢測有助於更早辨識患者，進而提高疾病通報效率，減少診斷延誤，最終提升整個醫療保健系統對免疫檢測標記檢測的需求。

微創血液檢測的普及正在加速免疫檢測的臨床應用。這是因為與腦脊髓液 (CSF) 檢測和成像技術相比，這些方法具有更高的患者依從性、更低的檢測風險和更強的可擴展性。基於血液的免疫檢測正在基層醫療和檢查室中實現常規檢測，從而擴大了神經系統疾病的診斷範圍。諸如高靈敏度數位免疫檢測技術（例如 Simoa 平台）等技術能夠以高診斷準確率檢測低濃度生物標記物，例如 pTau217 和神經絲輕鏈。例如，Fujiri Bio 的 Lumipulse G pTau217/BETA-澱粉樣蛋白 1-42 血漿比值檢測於 2025 年 5 月獲得 FDA 批准，這是一種用於檢測阿茲海默症病理的基於血液的免疫檢測。這些進步正在提高分析靈敏度、可重複性和處理能力，從而推動大規模臨床應用和更廣泛的市場滲透。

隨著神經生物標記在藥物研發和精準醫療中應用日益廣泛，神經生物標記免疫檢測產業也蓬勃發展。這是因為生物標記對於患者分層、治療監測和臨床試驗終點評估至關重要。隨著阿茲海默症疾病修正治療的不斷進步，對基於生物標記的精準診斷方法的需求日益成長，以便早期識別合格治療條件的患者。隨著對生物標記主導療法的依賴性不斷增強，免疫檢測的臨床效用也在不斷提高，進一步鞏固了其在推動個人化治療策略和改善神經系統疾病治療效果方面的作用。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：神經系統生物標記免疫檢測市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：全球神經系統生物標記免疫檢測市場：按產品分類的業務分析

  • 按產品分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按產品分類，2021-2033 年
  • 裝置
    • 設備市場，2021-2033年
  • 試劑
    • 試劑市場，2021-2033年
  • 服務
    • 服務市場，2021-2033年

第5章：神經系統生物標記免疫檢測市場：疾病特異性業務分析

  • 按疾病分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按疾病分類，2021-2033 年
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 其他

第6章：神經系統生物標記免疫檢測市場：按應用領域分類的業務分析

  • 按應用領域分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按應用領域分類，2021-2033年
  • 體外診斷應用
  • 研究用途

第7章：神經系統生物標記免疫檢測市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • QIAGEN
    • Abbott
    • Merck & Co., Inc.
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Sysmex Corporation
    • Merck KGaA.
    • F. Hoffmann-La Roche Ltd.
    • Nimble Therapeutics
Product Code: GVR-4-68040-039-6

Immunoassay For Neurological Biomarkers Market Summary

The global immunoassay for neurological biomarkers market size was estimated at USD 1.08 billion in 2025 and is projected to reach USD 2.12 billion by 2033, growing at a CAGR of 8.91% from 2026 to 2033. Growth is supported by the rising prevalence of neurodegenerative diseases, increasing demand for early diagnostics, wider adoption of minimally invasive blood-based testing, and advancements in high-sensitivity immunoassays.

Furthermore, the expanding use of neurological biomarkers in drug development and precision medicine. The growing demand for early diagnosis of neurological disorders is significantly supporting the immunoassay for neurological biomarkers market, as early-stage detection improves treatment outcomes and enables timely therapeutic intervention. Neurological diseases such as Alzheimer's often remain undiagnosed in early stages, creating a strong need for accessible diagnostic tools. For instance, in October 2025, F. Hoffmann-La Roche received U.S. FDA clearance for its Elecsys pTau181 blood-based immunoassay, designed to aid in the early detection of Alzheimer's disease in clinical and primary care settings. These tests help identify patients at earlier stages, improving referral efficiency, reducing diagnostic delays, and thereby increasing demand for immunoassay-based biomarker testing across healthcare systems.

The transition toward minimally invasive blood-based testing is accelerating the clinical adoption of immunoassays, as these methods offer improved patient compliance, reduced procedural risks, and greater scalability than cerebrospinal fluid (CSF) testing and imaging techniques. Blood-based immunoassays enable routine testing in primary care and laboratory settings, expanding access to neurological diagnostics. Technologies such as high-sensitivity digital immunoassays (e.g., Simoa platforms) enable the detection of low-abundance biomarkers, such as pTau217 and neurofilament light chain, with high diagnostic accuracy. For instance, in May 2025, Fujirebio received U.S. FDA clearance for its Lumipulse G pTau217/B-Amyloid 1-42 plasma ratio test, a blood-based immunoassay designed to detect Alzheimer's pathology. These advancements enhance analytical sensitivity, reproducibility, and throughput, supporting large-scale clinical deployment and broader market adoption.

The increasing integration of neurological biomarkers into drug development and precision medicine is supporting the growth of the immunoassays for neurological biomarkers industry, as biomarkers are critical for patient stratification, treatment monitoring, and clinical trial endpoint evaluation. The development of disease-modifying therapies for Alzheimer's disease has intensified the need for accurate biomarker-based diagnostics to identify eligible patients at early stages. This growing reliance on biomarker-driven approaches is enhancing the clinical utility of immunoassays and reinforcing their role in advancing personalized treatment strategies and improving outcomes in neurological care.

Global Immunoassay for Neurological Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global immunoassays for neurological biomarkers market report based on product, disease, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Reagents
  • Services
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • In Vitro Diagnostics Application
  • Research Application
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Immunoassays for Neurological Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Global Immunoassays for Neurological Biomarkers Market, by Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
  • 4.5. Reagents
    • 4.5.1. Reagents Market, 2021 - 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Alzheimer's Disease
    • 5.4.1. Alzheimer's Disease Market, 2021 - 2033 (USD Million)
  • 5.5. Parkinson's Disease
    • 5.5.1. Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • 5.6. Multiple Sclerosis
    • 5.6.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Application Business Analysis

  • 6.1. Application Market Share, 2025 & 2033
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. In Vitro Diagnostics Application
    • 6.4.1. In Vitro Diagnostics Application Market, 2021 - 2033 (USD Million)
  • 6.5. Research Application
    • 6.5.1. Research Application Market, 2021 - 2033 (USD Million)

Chapter 7. Immunoassays for Neurological Biomarkers Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. QIAGEN
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Abbott
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Johnson & Johnson Services, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Thermo Fisher Scientific, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bio-Rad Laboratories, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Sysmex Corporation
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Merck KGaA.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Nimble Therapeutics
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 4 Global immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 5 Global immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global immunoassays for neurological biomarkers market, by region, 2021 - 2033 (USD Million)
  • Table 7 North America immunoassays for neurological biomarkers market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 9 North America immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 10 North America immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 11 US immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 12 US immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 13 US immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 15 Canada immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 16 Canada immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 17 Mexico immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 18 Mexico immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 19 Mexico immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 20 Europe immunoassays for neurological biomarkers market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 22 Europe immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 23 Europe immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 24 UK immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 25 UK immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 26 UK immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 27 Germany immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 28 Germany immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 29 Germany immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 30 France immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 31 France immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 32 France immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 33 Italy immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 34 Italy immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 35 Italy immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 36 Spain immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 37 Spain immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 38 Spain immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 39 Denmark immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 40 Denmark immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 41 Denmark immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 42 Sweden immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 43 Sweden immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 44 Sweden immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 45 Norway immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 46 Norway immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 47 Norway immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific immunoassays for neurological biomarkers market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 52 Japan immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 53 Japan immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 54 Japan immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 55 China immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 56 China immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 57 China immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 58 India immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 59 India immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 60 India immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 61 Australia immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 62 Australia immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 63 Australia immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 64 Thailand immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 65 Thailand immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Thailand immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 67 South Korea immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 68 South Korea immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 69 South Korea immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 70 Latin America immunoassays for neurological biomarkers market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 72 Latin America immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 73 Latin America immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 74 Brazil immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 75 Brazil immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 76 Brazil immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 77 Argentina immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 78 Argentina immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 79 Argentina immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa immunoassays for neurological biomarkers market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 84 South Africa immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 85 South Africa immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 86 South Africa immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 90 UAE immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 91 UAE immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 92 UAE immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 93 Kuwait immunoassays for neurological biomarkers market, by product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait immunoassays for neurological biomarkers market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Kuwait immunoassays for neurological biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 96 Participant's overview
  • Table 97 Financial performance

List of Figures

  • Fig. 1 Immunoassays for neurological biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Immunoassays for neurological biomarkers market: Product outlook and key takeaways
  • Fig. 11 Immunoassays for neurological biomarkers market: Product movement analysis
  • Fig. 12 Global instruments market, 2021 - 2033 (USD Million)
  • Fig. 13 Global reagents market, 2021 - 2033 (USD Million)
  • Fig. 14 Global services market, 2021 - 2033 (USD Million)
  • Fig. 15 Immunoassays for neurological biomarkers market: Disease outlook and key takeaways
  • Fig. 16 Immunoassays for neurological biomarkers market: Disease movement analysis
  • Fig. 17 Global Alzheimer's disease market, 2021 - 2033 (USD Million)
  • Fig. 18 Global Parkinson's disease market, 2021 - 2033 (USD Million)
  • Fig. 19 Global multiple sclerosis market, 2021 - 2033 (USD Million)
  • Fig. 20 Global others market, 2021 - 2033 (USD Million)
  • Fig. 21 Immunoassays for neurological biomarkers market: Application outlook and key takeaways
  • Fig. 22 Immunoassays for neurological biomarkers market: Application movement analysis
  • Fig. 23 Global in vitro diagnostics application market, 2021 - 2033 (USD Million)
  • Fig. 24 Global research application market, 2021 - 2033 (USD Million)
  • Fig. 25 Immunoassays for neurological biomarkers market: Regional outlook and key takeaways
  • Fig. 26 North America Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Immunoassays for neurological biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework